Truxipicurium, a derivative of alpha-truxillic acid, a curare-like drug, is a neuromuscular blocking agent with rigid structure.

Tiametonium (also known as Thiamethon) is a lanthionamine derivative with ganglionic blocking activity. In preclinical models, Thiamethon prevents nicotine-induced convulsions in mice.

E7107 is a semisynthetic derivative of the natural product pladienolide B which was originally isolated from Streptomyces platensis. E7107 is the first compound a new class of anti-cancer agents targeting the spliceosome. Specifically E7107 interacts with the Splicing factor 3B subunit 1 (SF3b1) to block the normal splicing of oncogenes. Development of E7107 was suspended after Phase I clinical trials due to an unacceptable profile of adverse events.

Pirralkonium is the antiseptic agent.

Droclidinium is the muscarinic receptors antagonist. It is an anticholinergic, spasmolytic agent.

Fubromegan, a ganglionic blocking agent as an iodide salt, FUBROGONIUM IODIDE was used in Russia in patients with peptic ulcer and in the symptomatic therapy of patients with pneumoconioses. The antispasmodic effect of fubromegan was due to the effect on m- and n-cholinergic structures of smooth muscles and ganglia.